APOB and metabolic dysfunction-associated steatohepatitis: For the overall NASH population, mean (± SD) LDL-apoB FRR increased significantly from baseline to week 12 of ACCi therapy (31 ± 20.2 vs. 46 ± 22.6%/day, P = 0.03, N = 16, Fig. 2D), representing mean half-lives of 2.2 and 1.5 days, respectively.